Himanshu Kumar

About

Editor in Chief, (July 2018 - to date) International Reviews of Immunology (Taylor & Francis Group).

Department Head (Biological Sciences) from October 2023 till to December 2025)

Professor ( July 2022 - to date) Laboratory of Immunology and Infectious Disease Biology, Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India.

Associate Professor (August 2016 - June 2022), Laboratory of Immunology and Infectious Disease Biology, Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India.

Associate Editor in Chief, (March 2016 - July 2018) International Reviews of Immunology (Taylor & Francis Group).

Assistant Professor (July 2010-July 2016), Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India.

Adjunct Associate Professor. (March 2010-to date), Post-doctoralWorld Premier International Research Center (WPI), Immunology Frontier Research Center, Osaka University, Japan.

Associate/ Section Editor (May 2012 - March 2016), International Reviews of Immunology, Taylor & Francis.

JSPS Postdoctoral Fellow (April 2008-March 2010), Laboratory of Host Defense, World Premier International Research Center (WPI), Immunology Frontier Research Center, Osaka University, Japan.
​
Ph.D.[April 2004-March 2008 as Japanese Government Fellow (MEXT Fellow)], Immunobiology, Graduate School of Medicine, Osaka University, Japan with Professor. Shizuo Akira.

Employment

• Indian Institute of Science Education and Research, Bhopal Professor
  2022 - Present
• Indian Institute of Science Education and Research, Bhopal Associate Professor
  2016 - 2022
• Osaka University Adjunct Associate Professor
  2010 - Present
• The University of Osaka Post-doctoral (JSPS) training
  2008 - 2010

Education

• Osaka University PhD
• Lucknow University Masters in Science

Projects & Funding

Projects & funding information is unavailable.

Publications (88)

• miRBiT: a rules-based single-sample serum miRNA classifier for pan-cancer detection with multi-cohort validation
  Briefings in Bioinformatics 2026 DOI: 10.1093/bib/bbag189
  +Save
• Essential role of hsa-miR-203a-3p in type I interferons immune homeostasis during influenza and NDV infection
  RNA Biology 2026 DOI: 10.1080/15476286.2026.2640211
  +Save
• Global Pan-cancer serum miRNA classifier across 13 cancer types: Analysis of 46,349 clinical samples
  MedRxiv 2025 DOI: 10.1101/2025.02.07.25321821
  +Save
• HCMV detection in Asian gastric cancer RNA-seq data sets and clinical validation in Indian GC patients reveals the HCMV-GC specific gene signatures
  mSystems 2024 DOI: 10.1128/msystems.00673-24
  +Save
• Identification of gene classifier and modules associated with SARS-CoV-2 ARI in nasal swab
  Genes & Diseases 2024 DOI: 10.1016/J.GENDIS.2023.03.004
  +Save
• MicroRNA hsa-miR-203a-3p promotes H1N1 and NDV Virus Replication by suppressing the IFNA signaling
  BioRxiv 2024 DOI: 10.1101/2024.04.30.591875
  +Save
• Machine learning-driven blood transcriptome-based discovery of SARS-CoV-2 specific severity biomarkers
  Journal of Medical Virology 2023 DOI: 10.1002/JMV.28488
  +Save
• Dimensions of inflammation in host defense and diseases
  International Reviews of Immunology 2022 DOI: 10.1080/08830185.2022.2014174
  +Save
• Innate immune sensing of influenza A viral RNA through IFI16 promotes pyroptotic cell death
  IScience 2022 DOI: 10.1016/J.ISCI.2021.103714
  +Save
• How metabolism and metabolites shape immunity during disease
  International Reviews of Immunology 2022 DOI: 10.1080/08830185.2022.2061764
  +Save